How to Treat Multifocal Ta High-grade Disease if Bacillus Calmette-Guerin Is Unavailable

被引:2
|
作者
Witjes, Johannes Alfred [1 ]
Brausi, Maurizio [2 ]
Malmstrom, Per-Uno [3 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Geert Grootepl South 10, NL-6525 GA Nijmegen, Netherlands
[2] Urol Osped Carpi, Carpi, MO, Italy
[3] Univ Hosp Ing, Dept Surg Sci, Urol, Uppsala, Sweden
来源
EUROPEAN UROLOGY ONCOLOGY | 2020年 / 3卷 / 05期
关键词
pTa; Low grade; High grade; Multiple lesions; Cystectomy; Epirubicin; Gemcitabine; Chemohyperthermia; INVASIVE BLADDER-CANCER; HIGH-RISK; UROTHELIAL CARCINOMA; MITOMYCIN-C; PROGRESSION; RECURRENCE; THERAPY;
D O I
10.1016/j.euo.2019.06.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A 71-yr-old man was transferred to our institution with multiple and recurrent high-grade pTa bladder cancer 26 mo after an initial presentation of multiple and large pTa low-grade tumors and concomitant carcinoma in situ, treated with transurethral resection plus 6-mo postoperative mitomycin C. This case discusses several treatment options in the absence of bacillus Calmette-Guerin (BCG). Immediate radical cystectomy is an option with excellent survival, since there is a substantial risk of understaging and disease progression; however, this results in overtreatment in similar to 50% of these patients. Therefore, a conservative approach could be intravesical combination therapy such as gemcitabine/docetaxel or epirubicin/interferon. In addition, device-assisted intravesical therapy is becoming an option to consider. Finally, patients could be included in trials such as immunotherapy trials. Patient summary: This 71-yr-old patient was diagnosed with recurrent, moderately severe noninvasive bladder tumors, which were removed. The recommended additional therapy, intravesical bacillus Calmette-Guerin (BCG) instillations, was not available. Both the pros and the cons of radical surgery (bladder removal) and a more conservative approach (other intravesical treatments) are discussed. (c) 2019 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:705 / 709
页数:5
相关论文
共 50 条
  • [1] All High-Grade Ta Tumors Should be Classified as High Risk: Bacillus Calmette-Guerin Response in High-Grade Ta Tumors
    Bree, Kelly K.
    Hensley, Patrick J.
    Lobo, Niyati
    Brooks, Nathan A.
    Nogueras-Gonzalez, Graciela M.
    Guo, Charles C.
    Navai, Neema
    Grossman, H. Barton
    Dinney, Colin P.
    Kamat, Ashish M.
    JOURNAL OF UROLOGY, 2022, 208 (02): : 284 - +
  • [2] Bacillus Calmette-Guerin in Immunosuppressed Patient with High-Grade Nonmuscle Invasive Bladder Carcinoma
    Aznar Martinez, Laura
    Lopez Cubillana, Pedro
    Lopez Abadb, Alicia
    Vidal Crespo, Natalia
    Gomez Gomez, Guillermo Antonio
    UROLOGIA INTERNATIONALIS, 2019, 103 (02) : 242 - 244
  • [3] BACILLUS CALMETTE-GUERIN VERSUS SEQUENTIAL GEMCITABINE AND DOCETAXEL FOR TA HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER
    Eraky, Ahmed
    Hug, Brenda
    Kolanukuduru, Kaushik P.
    Ben-David, Reuben
    Almoflihi, Mohammed
    Waigankar, Nikhil
    Attalla, Kyrollis
    Wiklund, Peter
    Mehrazin, Reza
    Sfakianos, John P.
    JOURNAL OF UROLOGY, 2025, 213 (5S):
  • [4] Bacillus Calmette-Guerin (BCG) vaccination to treat endometriosis
    Hecht, Jonathan
    Suliman, Sara
    Wegiel, Barbara
    VACCINE, 2021, 39 (50) : 7353 - 7356
  • [5] BACILLUS CALMETTE-GUERIN IN TREATMENT OF NEOPLASTIC DISEASE
    LAUCIUS, JF
    BODURTHA, AJ
    MASTRANGELO, MJ
    CREECH, RH
    JOURNAL OF THE RETICULOENDOTHELIAL SOCIETY, 1974, 16 (06): : 347 - 373
  • [6] Genomic analysis of response to bacillus Calmette-Guerin treatment in high-grade stage 1 bladder cancer patients
    Sanders, J. Alexa
    Frasier, Connor
    Matulay, Justin T.
    Steuerwald, Nury M.
    Zhu, Jason
    Grigg, Claud M.
    Kearns, James T.
    Riggs, Stephen B.
    Gaston, Kris E.
    Brouwer, Cory R.
    Burks, R. Tucker
    Hartman, Aaron L.
    Foureau, David M.
    Burgess, Earle F.
    Clark, Peter E.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (07) : 2998 - +
  • [8] SUPPRESSION OF ADJUVANT DISEASE BY BACILLUS CALMETTE-GUERIN (BCG)
    SUTHERLAND, RIL
    QUAGLIATA, F
    EXPERIENTIA, 1975, 31 (03): : 367 - 369
  • [9] Phase I trial of intravesical Bacillus Calmette-Guerin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guerin treatment
    Alanee, Shaheen
    Sana, Sherjeel
    El-Zawahry, Ahmed
    Peabody, James
    Pearce, Tiffany
    Adams, Nicole
    Deebajah, Mustafa
    Crabtree, Jane
    Delfino, Kristin
    McVary, Kevin
    Robinson, Kathy
    Rao, Krishna
    WORLD JOURNAL OF UROLOGY, 2021, 39 (10) : 3807 - 3813
  • [10] Renal Tuberculosis Following Intravesical Bacillus Calmette-Guerin for High-grade Non-muscle-invasive Bladder Cancer
    Sihra, Neha
    Diasuke, Nonaka
    Thurairaja, Ramesh
    Khan, Muhammad Shamim
    Malde, Sachin
    UROLOGY, 2017, 107 : E3 - E4